| 000 | 01804 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514073702.0 | ||
| 264 | 0 | _c20040106 | |
| 008 | 200401s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/cncr.11512 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTalbot, Susan M | |
| 245 | 0 | 0 |
_aHigh-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. _h[electronic resource] |
| 260 |
_bCancer _cJul 2003 |
||
| 300 |
_a331-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIfosfamide _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMesna _xadministration & dosage |
| 650 | 0 | 4 |
_aMesothelioma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPleural Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aProtective Agents _xadministration & dosage |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aRankin, Cathryn | |
| 700 | 1 | _aTaub, Robert N | |
| 700 | 1 | _aBalcerzak, Stanley P | |
| 700 | 1 | _aBhoopalam, Nirmala | |
| 700 | 1 | _aChapman, Robert A | |
| 700 | 1 | _aBaker, Laurence H | |
| 700 | 1 | _aMiddleman, Edward L | |
| 700 | 1 | _aAntman, Karen H | |
| 773 | 0 |
_tCancer _gvol. 98 _gno. 2 _gp. 331-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.11512 _zAvailable from publisher's website |
| 999 |
_c12649854 _d12649854 |
||